As estimated worldwide in 2011, the number of peoples with diabetes were around 346 million and its number is unceasingly getting bigger. It is expected to be double in number by 2030. Diabetic retinopathy and diabetic macular edema is occurring, which leads to the vision loss. These adverse conditions mostly occur in patient having high blood sugar level and high blood pressure. Therefore, the consequential increase in growth of diabetic macular edema therapeutics pipeline is observed.
Diabetic macular edema became the foremost cause of vision loss in diabetic patients and working-aged adults. Diabetic macular edema is generally a building up of fluid in macula region in retina, which is present at the back of the eye and responsible for making sharp and straight-headed vision with macula. Swelling and thickening of macula majorly affecting vision by distorting it. The accumulation of fluid causes the leakage which can damage the blood vessels present near retina. The foremost cause of diabetic macular edema is diabetic retinopathy, but in some cases, it can subsequently occur after an eye surgery. It is also found that inflammation in eye can cause diabetic macular edema. Theprimary symptoms of diabetic macular edema is the wavy or blurred vision, in which colour may be faded. If it occurs to only one eye, the blurry vision will not be noticed until the condition become severe.
In March 2016, F Hoffmann-La Roche AG, Inc. started a Phase II clinical study on drug RO6867461, in participants with center-involving Diabetic macular edema. In November 2016, Regeneron Pharmaceuticals, Inc. started a Phase IIIb of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with Diabetic Macular Edema.
In December 2016, Nikon Corporation and its subsidiary Optos Plc have entered into an agreement of strategic development with Verily Life Sciences LLC, in the field of machine learning-enabled retinal imaging. The collaboration occurred for the development of technology and solutions for enhanced screening of diabetic retinopathy and diabetic macular edema by diabetes-treating physicians and others to assist in efficient referral of patients to eyecare specialists, and provide these specialists with assisted reading programs for easier diagnosis of disease. In March 2017, Clearside Biomedical Inc. and EyeKor, Inc. had entered into collaboration for supporting ophthalmic clinical trial activities of Clearside Biomedical Inc. EyeKor, Inc. is a Software-as-a-Service (SaaS) company providing image and data management solutions for ophthalmic clinical trials. And, Clearside Biomedical, Inc. will use ExcelsiorTM, EyeKor, Inc.’s 510(k)-cleared, cloud-based software platform, for both clinical and preclinical applications. In May 2015, R-Tech Ueno, Ltd. had planned to conduct a cooperative research with the group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology, Graduate School of Medicine from Hokkaido University. The collaboration occurred for research in development of a new VAP-1 inhibitor (Development Code:RTU-1096), for treatment of diabetic retinopathy and diabetic macular edema.
Some of the companies having a pipeline of diabetic macular edema therapeutics include Regeneron Pharmaceuticals, Inc., Bayer AG, Allergan, Clearside Biomedical, Inc., Novartis AG, Chengdu Kanghong Biotech Co., Ltd., ThromboGenics NV, F Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Inc.